A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.

A Phase 1, Open Label, Fixed Sequence Study to Investigate the Effect of Rabeprazole on the Pharmacokinetics of PF-08049820 in Healthy Chinese Adult Participants.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07284173

Enrollment

Registered

2025-12-16

Start date

2025-11-03

Completion date

2025-12-18

Last updated

2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Keywords

Healthy, Atopic Dermatitis

Brief summary

This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves. The study will take in healthy adult participants aged 18 to 65 years who are not able to have children. Eligible participants must weigh more than 50 kilograms (110 pounds) and have a Body Mass Index (BMI) between 18.5 and 27.9. Each participant will receive two treatments: * One treatment with PF-08049820 alone * One treatment with PF-08049820 taken together with rabeprazole Both medicines will be taken by mouth. Participants will stay at the study clinic for a few days during each treatment period. During these stays, the study team will collect blood samples to see how the body absorbs and processes the medicine.

Interventions

DRUGPF-08049820

Oral tablets

DRUGRabeprazole

Oral tablets

Study design

Allocation

Intervention model

SEQUENTIAL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Male and female participants of non-childbearing potential aged 18 to 65 years, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12-lead electrocardiogram. * BMI of 18.5-27.9 kg/m2; and a total body weight \>50 kg (110 lb). * Participants who are willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

* History or evidence of significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic diseases. * Positive test for HIV, hepatitis B (HBsAg), or hepatitis C (HCVAb). * Active or latent tuberculosis (TB) infection or inadequate treatment history for TB. * Any medical or psychiatric condition, including active suicidal ideation in the past year or suicidal behavior in the past 5 years, that may increase risk or interfere with study participation. * Current use of prohibited medications or inability/unwillingness to use required medications.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08049820.	Day 1 through Day 38-45
PK: Area under the plasma concentration (AUC) of PF-08049820	Day 1 through Day 38-45

Secondary

Measure	Time frame
Number of participants with treatment emergent adverse events	First dose through Day 38-45

Countries

China

Contacts

STUDY_DIRECTORPfizer CT.gov Call Center

Pfizer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026